<a href="https://www.tcspharms.com/pro/Daptomycin_103060-53-3_dose_class_side_effects_and_price.html" rel="nofollow ugc">daptomycin</a>, sold under the brand name cubicin among others, is a lipopeptide antibiotic used in the treatment of systemic and life-threatening infections caused by gram-positive organisms. it is a naturally occurring compound found in the soil saprotroph streptomyces roseosporus. its distinct mechanism of action makes it useful in treating infections caused by multiple drug-resistant bacteria. 
 
daptomycin was removed from the world health organization's list of essential medicines in 2019. the world health organization classifies daptomycin as critically important for human medicine. 
 
 
medical uses 
daptomycin is indicated for use in adults in the united states for skin and skin structure infections caused by gram-positive infections, s. aureus bacteraemia, and right-sided s. aureus endocarditis. it binds avidly to pulmonary surfactant, so cannot be used in the treatment of pneumonia. there seems to be a difference in working daptomycin on hematogenous pneumonia. 
 
adverse effects 
common adverse drug reactions associated with daptomycin therapy include: 
 
cardiovascular: low blood pressure, high blood pressure, swelling 
central nervous system: insomnia 
dermatological: rash 
gastrointestinal: diarrhea, abdominal pain 
hematological: eosinophilia 
respiratory: dyspnea 
other: injection site reactions, fever, hypersensitivity 
less common, but serious adverse events reported in the literature include 
 
hepatotoxicity: elevated transaminases 
nephrotoxicity: acute kidney injury from rhabdomyolysis 
also, myopathy and rhabdomyolysis have been reported in patients simultaneously taking statins, but whether this is due entirely to the statin or whether daptomycin potentiates this effect is unknown. due to the limited data available, the manufacturer recommends that statins be temporarily discontinued while the patient is receiving daptomycin therapy. creatine kinase levels are usually checked regularly while individuals undergo daptomycin therapy. 
 
in july 2010, the fda issued a warning that daptomycin could cause life-threatening eosinophilic pneumonia. the fda said it had identified seven confirmed cases of eosinophilic pneumonia between 2004 and 2010 and an additional 36 possible cases. the seven confirmed victims were all older than 60 and symptoms appeared within two weeks of initiation of therapy.